Home › Transthyretin-Related Hereditary Amyloidosis › District of Columbia › Washington
Transthyretin-Related Hereditary Amyloidosis clinical trials in Washington, DC
3 studies for Transthyretin-Related Hereditary Amyloidosis are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RecruitingObservational study
- Research Site, Washington D.C.
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute, Washington D.C.
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
RecruitingPhase 3
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute, Washington D.C.
Transthyretin-Related Hereditary Amyloidosis trials in other cities
- Los Angeles, CA5 studies
- New York City, NY5 studies
- Durham, NC4 studies
- Philadelphia, PA4 studies
- Baltimore, MD4 studies
- Portland, OR4 studies
- San Diego, CA4 studies
- Boston, MA4 studies
- Dallas, TX4 studies
- St. Louis, MO3 studies
- Kansas City, MO3 studies
- Houston, TX3 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.